4.5 Article

Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface

Journal

CHEMMEDCHEM
Volume 11, Issue 8, Pages 911-918

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201500484

Keywords

natural products; protein-protein interactions; semi-synthesis; small molecules; X-ray protein crystallography

Funding

  1. European Commission's Horizon Marie Sklodowska-Curie action (MSCA) [PIAPP-GA-2011-286418 14-3-3Stabs]
  2. Collaborative Research Center - Deutsche Forschungsgemeinschaft (DFG) [SFB1093]
  3. Deutsche Krebshilfe of the Mildred-Scheel Program [111815]
  4. DFG Excellence Initiative [GSC-4 SGBM, EXC 294 BIOSS]
  5. DFG Heisenberg program

Ask authors/readers for more resources

Small-molecule modulation of protein-protein interactions (PPIs) is one of the most promising new areas in drug discovery. In the vast majority of cases only inhibition or disruption of PPIs is realized, whereas the complementary strategy of targeted stabilization of PPIs is clearly under-represented. Here, we report the example of a semi-synthetic natural product derivativeISIR-005that stabilizes the cancer-relevant interaction of the adaptor protein 14-3-3 and Gab2. The crystal structure of ISIR-005 in complex with 14-3-3 and the binding motif of Gab2 comprising two phosphorylation sites (Gab2pS210pT391) showed how the stabilizing molecule binds to the rim-of-the-interface of the protein complex. Only in the direct vicinity of 14-3-3/Gab2pT391 site is a pre-formed pocket occupied by ISIR-005; binding of the Gab2pS210 motif to 14-3-3 does not create an interface pocket suitable for the molecule. Accordingly, ISIR-005 only stabilizes the binding of the Gab2pT391 but not the Gab2pS210 site. This study represents structural and biochemical proof of the druggability of the 14-3-3/Gab2 PPI interface with important implications for the development of PPI stabilizers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo

Corinna Spohr, Teresa Poggio, Geoffroy Andrieux, Katharina Schoenberger, Nina Cabezas-Wallscheid, Melanie Boerries, Sebastian Halbach, Anna L. Illert, Tilman Brummer

Summary: The presence of internal tandem duplications (ITD) in FMS-like tyrosine kinase 3 (FLT3) combined with DNMT3A mutations in acute myeloid leukemia (AML) leads to poor prognosis. Studies have shown that GAB2 is essential for the development of Flt3-ITD driven AML, with Gab2 deficient mice displaying prolonged survival and reduced pathology. Gab2 increases signaling of receptor tyrosine kinases, promoting AML aggressiveness and drug resistance, making it a promising biomarker and therapeutic target in human AML.

LEUKEMIA (2022)

Article Biochemistry & Molecular Biology

Long-term cell fate and functional maintenance of human hepatocyte through stepwise culture configuration

Go Sugahara, Yuji Ishida, Jae Jin Lee, Meng Li, Yasuhito Tanaka, Hyungjin Eoh, Yusuke Higuchi, Takeshi Saito

Summary: This study aimed to define the environmental requirements necessary for maintaining the homeostasis of terminally differentiated hepatocytes. The supplementation of dimethyl sulfoxide (DMSO) was found to be indispensable for mitigating fate deterioration and promoting adaptation to the in vitro environment. Dimethyl sulfone (DMSO2) was identified as a substitute for DMSO, supporting the long-term maintenance of hepatocyte morphology, marker gene expression, and functionality.

FASEB JOURNAL (2023)

Article Gastroenterology & Hepatology

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma

Gajanan Kendre, Karthikeyan Murugesan, Tilman Brummer, Oreste Segatto, Anna Saborowski, Arndt Vogel

Summary: This study retrospectively analyzed the genomic data of 6,130 patients diagnosed with intrahepatic cholangiocarcinoma (iCCA), and identified seven oncogenic driver genes and their co-mutational patterns. The study also discovered genetic variations and genomic patterns associated with iCCA, which are important for developing effective treatment strategies and predicting mechanisms of resistance.

JOURNAL OF HEPATOLOGY (2023)

Article Cell Biology

Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase

Lino Rohrer, Corinna Spohr, Carina Beha, Ricarda Griffin, Sandra Braun, Sebastian Halbach, Tilman Brummer

Summary: The dimerization of RAF kinases plays a crucial role in their activation and the activation of the RAS/ERK pathway. Recent studies have developed a split luciferase system to study the homo- and heterodimerization of BRAF, RAF1, and KSR1. It was found that KRAS(G12V) promotes the dimerization of BRAF, while KSR1 can form homo- and KSR1/BRAF heterodimers even in the absence of KRAS(G12V) through a salt bridge between the CC-SAM domain of KSR1 and the BRAF-specific region.

CELL COMMUNICATION AND SIGNALING (2023)

Article Oncology

Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model

Melanie Langhammer, Julia Schoepf, Timo Jaquet, Katharina Horn, Moritz Angel, Corinna Spohr, Daniel Christen, Franziska Maria Uhl, Tiago Maie, Henrike Jacobi, Thorsten B. Feyerabend, Julia Huber, Marcus Panning, Cassian Sitaru, Ivan Costa, Robert Zeiser, Konrad Aumann, Heiko Becker, Till Braunschweig, Steffen Koschmieder, Khalid Shoumariyeh, Michael Huber, Mirle Schemionek-Reinders, Tilman Brummer, Sebastian Halbach

Summary: The persistence of leukemic stem cells (LSCs) in chronic myeloid leukemia (CML) presents a challenge in therapy. This study investigates the role of mast cells (MCs) in CML progression and suggests targeting MCs as an additional approach for CML treatment. The BCR::ABL1 fusion gene drives the expansion of bone marrow-derived MCs and enhances their responsiveness to degranulation triggers. In CML patients, splenomegaly is associated with increased BM MC counts and elevated pro-inflammatory cytokines, indicating the importance of MCs in disease progression.

LEUKEMIA (2023)

Article Oncology

MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production

Marlene Langenbach, Sophie Giesler, Stefan Richtsfeld, Sara Costa-Pereira, Lukas Rindlisbacher, Tobias Wertheimer, Lukas M. Braun, Geoffroy Andrieux, Sandra Duquesne, Dietmar Pfeifer, Nadine M. Woessner, Hans D. Menssen, Sanaz Taromi, Justus Duyster, Melani Boerries, Tilman Brummer, Bruce R. Blazar, Susana Minguet, Patrick Turko, Mitchell P. Levesque, Burkhard Becher, Rober Zeiser

Summary: Treatment of metastatic melanoma with immune checkpoint inhibitors (ICI) has high response rates, but resistance to ICI impacts patient survival. In this study, the role of MDM2 inhibition in enhancing ICI therapy was investigated using mouse models and patient-derived melanoma cells. MDM2 inhibition induced expression of IL15 and MHC-II in melanoma cells through p53 induction. This enhanced antitumor immunity and induced anti-melanoma immune memory. In patients, increased IL15 and MHC-II expression correlated with better prognosis in WT melanoma but not TP53-mutated melanoma.

MOLECULAR CANCER RESEARCH (2023)

Meeting Abstract Oncology

EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA

Romain Sigaud, Anja Stefanski, Florian Selt, Thomas Hielscher, Diren Usta, Daniela Kocher, Daniel Picard, Isabel Budenbender, Marc Remke, Stefan M. Pfister, David T. W. Jones, Tilman Brummer, Olaf Witt, Till Milde

NEURO-ONCOLOGY (2023)

Meeting Abstract Oncology

DRUG-CLASS SPECIFIC GENE-BASED MAPK SENSITIVITY SCORES (MSS) PREDICT SENSITIVITY TO MAPK INHIBITORS AND IDENTIFY IMMUNE INFILTRATION AS PUTATIVE TARGET IN PEDIATRIC LOW-GRADE GLIOMAS

Romain Sigaud, Thomas K. Albert, Caroline Hess, Thomas Hielscher, Nadine Winkler, Carolin Walter, Daniel Muenter, Florian Selt, Diren Usta, Jonas Ecker, Angela Brentrup, Martin Hasselblatt, Christian Thomas, Julian Varghese, David Capper, Ulrich W. Thomale, Pablo Hernaiz Driever, Michele Simon, Svea Horn, Nina Annika Herz, Arend Koch, Felix Sahm, Stefan Hamel Mann, Augusto Faria Andrade, Nada Jabado, Antoinette Y. N. Schouten-van Meeteren, Eelco Hoving, Tilman Brummer, Cornelis M. van Tilburg, Stefan M. Pfister, Olaf Witt, David T. W. Jones, Kornelius Kerl, Till Milde

NEURO-ONCOLOGY (2023)

Article Multidisciplinary Sciences

MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas

Romain Sigaud, Thomas K. Albert, Caroline Hess, Thomas Hielscher, Nadine Winkler, Daniela Kocher, Carolin Walter, Daniel Muenter, Florian Selt, Diren Usta, Jonas Ecker, Angela Brentrup, Martin Hasselblatt, Christian Thomas, Julian Varghese, David Capper, Ulrich W. Thomale, Pablo Hernaiz Driever, Michele Simon, Svea Horn, Nina Annika Herz, Arend Koch, Felix Sahm, Stefan Hamelmann, Augusto Faria-Andrade, Nada Jabado, Martin U. Schuhmann, Antoinette Y. N. Schouten-van Meeteren, Eelco Hoving, Tilman Brummer, Cornelis M. van Tilburg, Stefan M. Pfister, Olaf Witt, David T. W. Jones, Kornelius Kerl, Till Milde

Summary: The authors develop MAPKi sensitivity scores (MSS) to predict response to MAPKi in pediatric low-grade gliomas (pLGG) and validate their effectiveness using bulk and single-cell sequencing datasets. The MSSs successfully distinguish sensitive and non-sensitive cells and correlate with treatment response in independent datasets. These MSSs are important for patient stratification and should be validated in clinical trials.

NATURE COMMUNICATIONS (2023)

Article Multidisciplinary Sciences

BRAFΔß3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability

Manuel Lauinger, Daniel Christen, Rhena F. U. Klar, Carole Roubaty, Christoph E. Heilig, Michael Stumpe, Jennifer J. Knox, Nikolina Radulovich, Laura Tamblyn, Irene Y. Xie, Peter Horak, Andrea Forschner, Michael Bitzer, Uwe A. Wittel, Melanie Boerries, Claudia R. Ball, Christoph Heining, Hanno Glimm, Martina Froehlich, Daniel Huebschmann, Steven Gallinger, Ralph Fritsch, Stefan Froehling, Grainne M. O'Kane, Joern Dengjel, Tilman Brummer

Summary: This study functionally characterizes BRAF exon 12 deletions and compares them with other BRAF ss 3-alpha C mutants. It demonstrates that BRAF(Delta ss 3-alpha C) deletion mutants form stable dimers and multiprotein complexes, and their dimerization is necessary. Some mutants with aromatic amino acid insertions at the deletion junction exhibit resistance to monomer-favoring RAF inhibitors while being sensitive to dimer-favoring inhibitors.

SCIENCE ADVANCES (2023)

Meeting Abstract Oncology

THE FIRST-IN-CLASS ERK INHIBITOR ULIXERTINIB (BVD-523) SHOWS ACTIVITY IN MAPK-DRIVEN PEDIATRIC LOW-GRADE GLIOMA MODELS AS SINGLE AGENT AND IN COMBINATION WITH MEK INHIBITORS OR SENOLYTICS

Romain Sigaud, Lisa Roesch, Charlotte Gatzweiler, Julia Benzel, Laura von Soosten, Heike Peterziel, Sara Najafi, Simay Ayhan, Xena F. Gerloff, Nina Hofmann, Isabel Buedenbender, Kathrin I. Foerster, Juergen Burhenne, Remi Longuespee, Cornelis M. van Tilburg, David T. W. Jones, Stefan M. Pfister, Deborah Knoerzer, Brent Kreider, Max Sauter, Kristian W. Pajtler, Marc Zuckermann, Ina Oehme, Olaf Witt, Till Milde

NEURO-ONCOLOGY (2022)

Meeting Abstract Oncology

MOLECULAR IMPLICATIONS OF MITOGEN-ACTIVATED PROTEIN KINASE PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA

Romain Sigaud, Anja Stefanski, Florian Selt, Thomas Hielscher, Diren Usta, Daniela Kocher, Daniel Picard, Isabel Buedenbender, Marc Remke, Stefan M. Pfister, David T. W. Jones, Tilman Brummer, Olaf Witt, Till Milde

NEURO-ONCOLOGY (2022)

Meeting Abstract Oncology

PREVENTING RECURRENCE: TARGETING MOLECULAR MECHANISMS DRIVING TUMOR GROWTH REBOUND AFTER MAPKI WITHDRAWAL IN PEDIATRIC LOW-GRADE GLIOMA

Daniela Kocher, Florian Selt, Gintvile Valinciute, Julia Zaman, David Vonhoeren, Stefan Pusch, Romain Guiho, Juan Pedro Martinez-Barbera, Andreas von Deimling, Stefan M. Pfister, David T. W. Jones, Tilman Brummer, Olaf Witt, Till Milde, Romain Sigaud

NEURO-ONCOLOGY (2022)

Article Medicine, Research & Experimental

RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells

Lena Hoelzen, Jan Mitschke, Claudia Schoenichen, Maria Elena Hess, Sophia Ehrenfeld, Melanie Boerries, Cornelius Miething, Tilman Brummer, Thomas Reinheckel

Summary: This study suggests that proteases can act synergistically with PI3K inhibition in breast cancer cells, leading to enhanced therapeutic outcomes. Through a series of experiments, the researchers identified Usp7, Metap1, and Metap2 as key proteases that exhibit synthetic lethal effects when combined with PI3K inhibitors.

THERANOSTICS (2022)

No Data Available